Table 2: Change in HAQ-DI score at month 3 (from baseline).

Study Total ( )Tofacitinib 5 mg bdTofacitinib 10 mg bdPlaceboAdalimumab 40 mg every 2 weeks

Burmester et al. [15]399−0.43 −0.46 −0.18
Fleischmann et al. [16]611−0.50**−0.57**−0.19
Kremer et al. [17]
792−0.46 −0.56 −0.21
van der Heijde et al. [18]797−0.40#−0.54 −0.15
van Vollenhoven et al. [19]717−0.55**−0.61**−0.24−0.49**
Fleischmann et al. [20]384−0.51*−0.66 −0.25
Kremer et al. [21]
507−0.49**−0.39*−0.16
Tanaka et al. [22]140
−0.49**−0.57**−0.05

Significant ; **significant ; significant ; #significance not declared.